Neuroinflammation and functional connectivity in Alzheimer's disease: interactive influences on cognitive performance

https://doi.org/10.1523/JNEUROSCI.2574-18.2019

Cite as: J. Neurosci 2019; 10.1523/JNEUROSCI.2574-18.2019

Received: 5 October 2018
Revised: 25 March 2019
Accepted: 11 April 2019

This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published.
Neuroinflammation and functional connectivity in Alzheimer’s disease: interactive influences on cognitive performance

L. Passamonti¹*, K.A. Tsvetanov¹*, P.S. Jones¹, W.R. Bevan-Jones², R. Arnold², R.J. Borchert¹, E. Mak², L. Su², J.T. O’Brien²#, J.B. Rowe¹,³#

Joint *first and #last authorship

Authors’ addresses
¹Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
²Department of Psychiatry, University of Cambridge, Cambridge, UK
³Cognition and Brain Sciences Unit, Medical Research Council, Cambridge, UK

Corresponding Author
Luca Passamonti,
Department of Clinical Neurosciences
University of Cambridge
CB2 0SZ, UK
Telephone: +44.01223.330293
Email: lp337@medschl.cam.ac.uk

Short title (≤50 char.): Neuroinflammation-driven connectivity changes in AD (47 char.)

Title (≤ 50 words):

Number of words for abstract (≤ 250): 237
Number of words in the significance statement (≤120): 96
Number of words for introduction (≤650): 519
Number of words for discussion (≤1,500): 999
Number of figures and tables: 5 figures, 1 table
Total references: 50
Number of pages: 25

Acknowledgments & Conflict of Interest

We thank our volunteers and the radiographers/technologists at WBIC and PET/CT, Addenbrooke’s Hospital, for their invaluable support in data acquisition. We thank the NIHR Eastern Dementias and Neurodegenerative Diseases Research Network for help with subject recruitment. We thank Dr Istvan Boros and others at WBIC RPU for the manufacture of [¹¹C]PK11195 and [¹¹C]PiB. This study was funded by the National Institute for Health Research Cambridge Biomedical Research Centre and Biomedical Research Unit in Dementia (NIHR, RG64473), the Wellcome Trust (JBR 103838), and the Medical Research Council (RG91365/SUAG/004 and MR/P01271X/1). Dr. Li Su is supported by Alzheimer’s Research UK. L. Passamonti, K. Tsvetanov, W.R. Bevan-Jones, P.S. Jones, R. Arnold, R. Borchert, E. Mak, and L. Su report no financial disclosures or conflict of interest relevant to the manuscript. J.T. O’Brien has served as deputy editor of International Psychogeriatrics, received grant support from Avid (Lilly), and served as a consultant for Avid and GE Healthcare, all for matters not related to the current study. J.B. Rowe serves as editor to Brain, has been a consultant for Asceneuron and Syncona, and has received academic grant funding from AZ-MedImmune, Janssen, and Lilly, unrelated to this study.
Abstract

Neuroinflammation is a key part of the etio-pathogenesis of Alzheimer’s disease. We test the relationship between neuroinflammation and the disruption of functional connectivity in large-scale networks, and their joint influence on cognitive impairment.

We combined \[^{11}C\]PK11195 positron emission tomography (PET) and resting-state functional magnetic resonance imaging (rs-fMRI) in 28 humans (12 females/16 males) with clinical diagnosis of probable Alzheimer’s disease or mild cognitive impairment with positive PET biomarker for amyloid, and 14 age-, sex-, and education-matched healthy humans (8 females/6 males). Source-based ‘inflammetry’ was used to extract principal components of \[^{11}C\]PK11195 PET signal variance across all participants. rs-fMRI data were pre-processed via independent component analyses to classify neuronal and non-neuronal signals. Multiple linear regression models identified sources of signal co-variance between neuroinflammation and brain connectivity profiles, in relation to group and cognitive status.

Patients showed significantly higher \[^{11}C\]PK11195 binding relative to controls, in a distributed spatial pattern including the hippocampus, medial, and inferior temporal cortex. Patients with enhanced loading on this \[^{11}C\]PK11195 binding distribution displayed diffuse abnormal functional connectivity. The expression of a stronger association between such abnormal connectivity and higher levels of neuroinflammation correlated with worse cognitive deficits.

Our study suggests that neuroinflammation relates to the pathophysiological changes in network function that underlie cognitive deficits in Alzheimer’s disease. Neuroinflammation, and its association with functionally-relevant reorganisation of brain networks, is proposed as a target for emerging immuno-therapeutic strategies aimed at preventing or slowing the emergence of dementia.

Significance Statement

Neuroinflammation is an important aspect of Alzheimer’s disease (AD), but it was not known whether the influence of neuroinflammation on brain network function in humans was important for cognitive deficit.

Our study provides clear evidence that in vivo neuroinflammation in AD impairs large-scale network connectivity; and that the link between inflammation and functional network connectivity is relevant to cognitive impairment.

We suggest that future studies should address how neuroinflammation relates to network function as AD progresses; and whether the neuroinflammation in AD is reversible, as the basis of immunotherapeutic strategies to slow the progression of AD.
Introduction

Neuroinflammation plays a key role in the etio-pathogenesis of Alzheimer’s disease and other neurodegenerative disorders (Edison et al., 2008; Fernandez-Botran et al., 2011; Fan et al., 2015; Stefanetti et al., 2016). Pre-clinical models (Heppner et al., 2015; Hoeijmakers et al., 2016; Villegas-Llerena et al., 2016; Li et al., 2018; Wang et al., 2018), and research in humans (Fernandez-Botran et al., 2011; Edison et al., 2013; Fan et al., 2015; Stefaniak and O’Brien, 2016; Passamonti et al., 2018), demonstrate that microglia, the brain’s innate immune system, are activated in Alzheimer’s and other neurodegenerative diseases. Furthermore, genetic association studies have demonstrated a link between Alzheimer’s disease and polymorphisms or mutations in genes linked to immune responses (Villegas-Llerena et al., 2016). Although the mechanisms and mediators of inflammatory risk in Alzheimer’s disease are not fully understood, synaptic and neuronal injury may arise from the release of cytokines and pro-inflammatory molecules such as interleukin-1β and TGF-β (Fernandez-Botran et al., 2011), or direct microglial injury to synapses (Hong and Stevens, 2016; Hong et al., 2016). These, in turn, impair synaptic function, network communication, and may accelerate neurodegeneration and synaptic loss (Heppner et al., 2015; Hoeijmakers et al., 2016; Villegas-Llerena et al., 2016; Li et al., 2018; Wang et al., 2018).

Clinical studies of neuroinflammation in dementia have exploited positron emission tomography (PET) ligands that bind to the mitochondrial translocator protein (TSPO) in activated microglia (Cagnin et al., 2001; Gerhard et al., 2006a, 2006b; Edison et al., 2008, 2013; Fan et al., 2015; Passamonti et al., 2018). For example, relative to controls, patients with Alzheimer’s disease have higher [11C]PK11195 binding in the hippocampus, other...
medial-temporal lobe regions, and posterior cortices such as the pre-cuneus, which in turn correlates with cognitive severity (Passamonti et al., 2018).

These findings raise the possibility of immunotherapeutic strategies to prevent or slow the progression of Alzheimer’s disease. However, key issues remain to be resolved before such therapeutic strategies can be realised. For example, it is necessary to show how neuroinflammation is linked to cognitive deficits. A critical and unanswered question is whether regional neuroinflammation changes the functional connectivity of large-scale networks. Such large-scale neural networks represent an intermediate phenotypic expression of pathology in many diseases, that can be non-invasively quantified with resting-state functional magnetic resonance imaging. A challenge is that neither the anatomical substrates of cognition nor the targets of neurodegenerative disease are mediated by single brain regions: they are in contrast distributed across multi-variate and interactive networks.

We thus undertook a multi-modal and multi-variate neuroimaging study to combine $[^{11}C]$PK11195 quantification of distributed neuroinflammation with resting-state functional imaging in patients at different stages of Alzheimer’s disease. We used “source-based inflammetry” (analogous to ‘volumetry’) to reduce the dimensionality (i.e., complexity) of the neuroinflammation signal, and employed multiple linear regression models to associate neuroinflammation, functional network connectivity components, and cognition.

We tested two hypotheses:

1) that spatially distributed neuroinflammation related to significant changes in large-scale functional connectivity in patients with Alzheimer’s disease, relative to controls.

2) that the relationship between neuroinflammation and abnormal functional connectivity mediates cognitive deficit in Alzheimer’s disease.
Participants & Methods

Participants

The study was conducted in the context of the Neuroimaging of Inflammation in Memory and Other Disorders (NIMROD) study (Bevan-Jones et al., 2017). We included 14 patients meeting clinical diagnostic criteria for probable Alzheimer’s disease (McKhann et al., 2011), and 14 patients with mild cognitive (MCI) patients (12 females and 16 males in total) defined by: i) a mini-mental score examination >24/30; ii) memory impairment at least 1.5 standard deviations below that expected for age and education (Petersen et al., 1999); iii) biomarker evidence of amyloid pathology (positive Pittsburgh Compound-B PET scan) (MCI+) (Okello et al., 2009). We combined patients with clinical Alzheimer’s disease and MCI+ on the basis that these two groups represent a continuum of the same clinical spectrum (Okello et al., 2009).

Fourteen age-, sex-, and education-matched healthy controls (8 females and 6 males) were recruited with no history of major psychiatric or neurological illnesses, head injury or any other significant medical co-morbidity. All participants were aged over 50 years, with premorbid proficiency in English for cognitive testing, did not have any acute infectious or chronic symptomatic systemic inflammatory disorder (e.g., lupus, rheumatoid arthritis, etc.), or contra-indications to magnetic resonance imaging. Patients were identified from the Cambridge University Hospitals NHS Trust Memory Clinics and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN), while healthy controls were recruited via DeNDRoN. Participants had mental capacity and gave written consent in accordance with the Declaration of Helsinki. The study was approved by the local research ethics committee.
Clinical and cognitive assessment

Clinical indices of cognitive deficit included Mini Mental State Examination (MMSE), Addenbrooke’s Cognitive Examination-Revised (ACE-R), and Rey auditory verbal learning test (RAVLT). The demographic and neuropsychological measures are reported in Table 1. A Principal Component Analysis on the total MMSE, ACE-R, and RAVLT scores was conducted to reduce the dimensionality of the cognitive deficit into one latent variable which summarized the largest portion of shared variance as the first principal component.

Experimental design

Structural and functional magnetic resonance imaging protocols and pre-processing

Structural and functional magnetic resonance imaging was performed using a 3 Tesla Siemens Tim Trio scanner with a 32-channel phased-array head coil. A T1-weighted magnetization-prepared rapid gradient-echo image was acquired with repetition time=2300 ms, echo time=2.98 ms, matrix=256x240, in-plane resolution of 1x1 mm, 176 slices of 1 mm thickness, inversion time=900ms and flip angle=9 degrees. The co-registered T1 images were used in a multi-channel segmentation to extract probabilistic maps of 6 tissue classes: grey-matter, white-matter, cerebrospinal fluid, bone, soft tissue, and residual noise. The native-space grey-matter and white-matter images were submitted to diffeomorphic registration to create group template images (Ashburner, 2007). The template was normalised to the Montreal Neurological Institute (MNI) template using a 12-parameter affine transformation. After applying the normalisation parameters from the T1 stream to warp pre-processed functional images into MNI space, the normalised images were smoothed using an 8-mm Gaussian kernel. An estimate of total grey-matter, used in between-subject analysis as a covariate of no interest, was calculated as the median grey-
matter tissue intensity in a group mask based on voxels with grey-matter tissue probability of 0.3 across all individuals. Resting state multi-echo functional imaging was carried out for 11 min. A total of 269 echo-planar image volumes were acquired with repetition time=2430ms, echo times=13.00, 30.55 and 48.10 ms, matrix=64x64, in-plane resolution of 3.75x3.75 mm, 34 slices of 3.8 mm thickness with an inter-slice gap of 0.38 mm, and a Generealized Autocalibrating Partial Parallel Acquisition (GRAPPA) imaging with an acceleration factor of 2 and bandwidth=2368 Hz/pixel. The first six volumes were discarded to eliminate saturation effects and achieve steady-state magnetization. Pre-processing of resting-state data employed the Multi-Echo Independent Components Analysis (ME-ICA) pipeline, which uses independent component analysis to classify blood oxygenation dependant (BOLD) and non-BOLD signals based on the identification of linearly dependent and independent echo-time related components (https://wiki.cam.ac.uk/bmuwiki/MEICA) (Kundu et al., 2013). This provides an optimal approach to correct for movement-related and non-neuronal signals, and is therefore particularly suited to our study, in which systematic differences in head position might have been expected between groups. After ME-ICA, the data were smoothed with 5.9 mm full-width half maximum kernel.

The location of the key cortical regions in each network was identified by spatial independent component analysis (ICA) using the Group ICA of fMRI Toolbox (Calhoun et al., 2001) in an independent dataset of 298 age-matched healthy individuals from the population-based cohort in the Cambridge Centre for Ageing and Neuroscience (Cam-CAN) (Shafto et al., 2014). Details about pre-processing and node definition are published previously (Tsvetanov et al., 2016). Four networks were identified by spatially matching to pre-existing templates (Shirer et al., 2012). The default mode network contained five nodes: the ventromedial prefrontal cingulate cortex, dorsal and ventral posterior conjugate cortex,
and right and left inferior parietal lobes. The fronto-parietal network was defined using bilateral superior frontal gyrus and angular gyrus. Subcortical nodes included nodes having differential group accumulation of \([^{11}\text{C}]\text{PK11195}\), namely, bilateral putamen and hippocampus. The node time-series were defined as the first principal component resulting from the singular value decomposition of voxels in a 8-mm radius sphere, which was centred on the peak voxel for each node (Tsvetanov et al., 2016).

After extracting nodal time-series we sought to reduce the effects of noise confounds on functional connectivity effects of node time-series using a general linear model (Geerligs et al., 2017). This model included linear trends, expansions of realignment parameters, as well as average signal in the white-matter and cerebrospinal, including their derivative and quadratic regressors from the time-courses of each node (Satterthwaite et al., 2013). The signals in the white-matter and cerebrospinal fluid were created by using the average across all voxels with corresponding tissue probability larger than 0.7 in associated tissue probability maps available in the SPM12 software (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine transform set in the general linear model, ensuring that nuisance regression and filtering were performed simultaneously (Hallquist et al., 2013; Lindquist et al., 2018). The general linear model excluded the initial five volumes to allow for signal equilibration. The total head motion for each participant, which was used in subsequent between-subject analysis as a covariate of no interest (Geerligs et al., 2017), was quantified using the approach reported in Jenkinson and colleagues (Jenkinson et al., 2002), i.e. the root mean square of volume-to-volume displacement. Finally, the functional connectivity between each pair of nodes was computed using Pearson’s correlation on post-processed time-series.
Positron emission tomography (PET) protocols and pre-processing

All participants underwent $[^{11}\text{C}]$PK11195 PET imaging to assess the extent and distribution of neuroinflammation while patients with mild cognitive impairment (MCI) also underwent $[^{11}\text{C}]$PiB PET scanning to evaluate the degree of beta-amyloid. $[^{11}\text{C}]$PK11195 and $[^{11}\text{C}]$PiB PET were produced with high radiochemical purity (>95%), with $[^{11}\text{C}]$PiB PET having a specific activity >150 GBq/μmol at the end of synthesis, while $[^{11}\text{C}]$PK11195 specific activity was around 85 GBq/μmol at the end of synthesis. PET scanning used a General Electric (GE) Advance PET scanner (GE Healthcare, Waukesha, WI) and a GE Discovery 690 PET/CT, with attenuation correction provided by a 15min 68Ge/68Ga transmission scan and a low dose computed tomography scan, respectively. The emission protocols were 550 MBq $[^{11}\text{C}]$PiB injection followed by imaging from 40-70 minutes post-injection, and 75 minutes of dynamic imaging (55 frames) starting concurrently with a 500 MBq $[^{11}\text{C}]$PK11195 injection. Each emission frame was reconstructed using the PROMIS 3-dimensional filtered back projection algorithm into a 128x128 matrix 30cm trans-axial field of view, with a trans-axial Hann filter cut-off at the Nyquist frequency (Kinahan and Rogers, 1989). Corrections were applied for randoms, dead time, normalization, scatter, attenuation, and sensitivity.

For $[^{11}\text{C}]$PiB we used reference tissue region of interest (ROI) defined by ≥ 90% on the SPM8 grey-matter probability map (smoothed to PET resolution) in the cerebellar cortex (Schuitemaker et al., 2007). For $[^{11}\text{C}]$PK11195, supervised cluster analysis was used to determine the reference tissue time-activity curve (Turkheimer et al., 2007). $[^{11}\text{C}]$PiB data were quantified using standardized uptake value ratio (SUVR) by dividing the mean cerebrospinal fluid (CSF) corrected radioactivity concentration in each Hammers atlas ROI by the corresponding mean CSF-corrected radioactivity concentration in the reference tissue ROI (whole cerebellum). $[^{11}\text{C}]$PiB data were treated as dichotomous measures (i.e., positive...
or negative) and considered positive if the average SUVR value across the cortical ROIs was 
> 1.5 (Hatashita and Yamasaki, 2010). For $[^{11}\text{C}]$PK11195 maps of non-displaceable binding 
potential ($\text{BP}_{\text{ND}}$), a measure of specific binding, were determined using a basis function 
implementation of the simplified reference tissue model, both with and without CSF 
contamination correction (Gunn et al., 1997). $[^{11}\text{C}]$PK11195 $\text{BP}_{\text{ND}}$ maps (termed here PK 
maps for simplicity) were also generated using this basis function approach.

The PK maps were co-registered and warped to the Montreal Neurological Institute 
(MNI) space using the flow fields. To minimise the noise effects from non grey-matter 
regions, the normalised PK maps were masked with a group-based grey-matter mask based 
on voxels having grey-matter tissue probability larger than 0.3 in grey-matter segmented 
images across all individuals. The normalised images were smoothed using a 6mm Gaussian 
kernel. We then used independent component analysis across participants to derive spatial 
patterns of PK maps across voxels expressed by the group in a small number of independent 
components. All PK maps were spatially concatenated and submitted to Source-Based 
‘inflammometry’ (SBI) to decompose images across all individuals in a set of spatially 
independent sources without providing any information about the group (Xu et al., 2009), 
using the GIFT toolbox. Specifically, the $n$-by-$m$ matrix of participants-by-voxels was 
decomposed into: (i) a source matrix that maps each independent component to voxels 
(here referred to as $\text{PK}_{\text{IC}}$ maps), and (ii) a mixing matrix that maps $\text{PK}_{\text{IC}}$s to participants. The 
mixing matrix consists of loading values (one per participant) indicating the degree to which 
a participant expresses a defined $\text{PK}_{\text{IC}}$. The independent component loading values for the 
$\text{PK}_{\text{IC}}$ were taken forward to between-participant analysis of functional connectivity (Figure 
1), if they were (a) differentially expressed by controls and patients with Alzheimer’s disease.
pathology; and (b) were associated with atrophy (see results section and Fig.3). Only 1 dependent variable (IC3) met these criteria.

**Statistical analyses**

We adopted a two-level procedure, in which, at the first-level, we sought to identify functional connectivity differences associated with differences in $^{11}$C]PK11195 binding. In a second-level analysis, we tested whether individual variability in functional connectivity (from first-level analysis) is specifically associated with variability in cognitive decline in the group of patients with Alzheimer’s disease pathology.

Details about the first-level analysis approach are published previously (Tsvetanov et al., 2018). In short, we used multiple linear regression with well-conditioned shrinkage regularization (Ledoit and Wolf, 2004) to identify correlated structured sources of variance between functional connectivity and neuroinflammation measures. In particular, this analysis describes the linear relationship between functional connectivity and PK maps on a between-subject level, in terms of structure coefficients (Thompson and Borrello, 1985), by providing a linear combination of the functional connectivity measures, which we term *brain scores*, that are optimised to be highly correlated with the between-subject variability in the expression of the PK maps. Namely, brain-wide connectivity strength for each individual defined the independent variables, and PK$_i$ subject-specific loading values for group differentiating components were employed as dependent variable.

To identify and exclude potential outliers, Grubbs’ test was used (Grubbs, 1969; Barnett and Lewis, 1994). None of the loading values in the IC3 were outlying observations. Furthermore, to down-weight the effects of extreme or imprecise data points, analyses used robust linear regression.
To avoid overfitting, first-level multiple linear regression model was integrated with a 5-Fold Cross–Validation (Thompson and Borrello, 1985). To minimize the non-negligible variance of traditional k-Fold cross-validation procedure, we repeated each k-Fold 1,000 times with random partitioning of the folds to produce an R-value distribution, for which we report the median values.

Next, we tested the hypothesis that the effect of neuroinflammation on functional connectivity was related to cognitive deficits, in patients relative to controls. To this end, we performed a second-level multiple linear regression (MLR) analysis. Independent variables included subjects’ brain scores from first level MLR (reflecting how strongly each individual expressed the whole brain pattern of functional connections weighted by the IC3- PET derived data), group information, and their interaction term (brain scores x group).

In other words, we examined the linear relationship between functional connectivity and PK maps on a between-subject level, in terms of structure coefficients (Thompson and Borrello, 1985). We use multiple linear regression to identify a linear combination of the functional connectivity measures, which we term brain scores, that are optimised to be highly correlated with the between-subject variability in the expression of the PK maps. More specifically, the whole-brain connectivity strength for each individual defined the independent variables ($m \times n$), and PKIC subject-specific loading values for the sole group differentiating component were employed as dependent variable ($m \times 1$), where $m$ is the number of subjects and $n$ is the number of pairwise connections. This produced a set of structure coefficients ($1 \times n$) and a set of subject scores ($m \times 1$) for the functional connectivity data. The structure coefficients reflect the contribution of each connection to the overall functional connectivity pattern—conceptually similar to the component loadings in a principal component analysis on cognitive data and the source matrix in group ICA on
PET-PK data (here called source based ‘inflammetry’, SBI). The brain scores indicated how strongly an individual expresses the functional connectivity pattern which is conceptually similar to the subject-specific scores in a PCA and subject-specific loadings in the SBI analysis. These brain scores were correlated with the subjects’ cognitive performance, in a second-level multiple linear regression analysis. For the cognitive performance, we did not choose a single test, but rather a summarised cognitive ability score in terms of the first principal component across three cognitive tests. Covariates of no interest included age, gender, head movement, and global grey-matter volume.

Results

Source-based ‘inflammetry’

The optimal number of components (n=5) was detected with minimum-distance length criteria. One component showed significant differences between the patient and control groups in terms of their loading values (PKIC3, t-value = -2.1, p-value = 0.04) (Figure 2 right panel). The spatial extent of this PKIC3 included voxels with high values in cortical and subcortical regions, including the inferior temporal cortex and hippocampus, indicating that individuals with higher loading values, in this case the patient group, had higher [11C]PK11195 binding in these regions, relative to the control group (Figure 2, left panel). The other components did not differentiate patients from controls (Figure 3, first row).

The PKIC3 component, which differed between patients and controls, was the only PK component that negatively correlated with total grey-matter values in patients but not controls (Figure 3, second and third row). In other words, the patients expressing higher [11C]PK11195 binding showed also higher levels of cortical atrophy (Figure 3, second and
third row). This result was obtained when including the grey-matter volume as a covariate of no interest in the analysis, which suggests that the reported association was over and above the effects of overall brain atrophy.

All in all, our findings imply that the PKIC3 component reflects specific patterns of neuroinflammation and neurodegeneration in Alzheimer’s disease. These patterns were next tested in terms of their relevance for changes in large-scale network function and their interactive effect in predicting cognitive deficit in Alzheimer’s disease.

**Functional connectivity**

As expected, there was strong positive functional connectivity between all nodes within the four networks, identified by spatially matching to pre-existing templates (Figure 4, left panel). In terms of group differences, the functional connectivity within networks (within the default mode network, within the fronto-parietal network, left-right putamen and left-right hippocampus) and between the default mode network and hippocampus was weaker in patients relative to controls (Figure 4, right panel). Furthermore, the connectivity between the putamen and hippocampus increased while the connectivity between default mode network and putamen was less negative for patients relative to controls.

**Functional connectivity and neuroinflammation**

The first-level multiple linear regression model assessing the relationship between PKIC3 maps and functional connectivity data was significant ($r=0.52$, $p<0.001$). The standard coefficients indicated a positive association between the PKIC3 loading values and variability in functional connectivity (Figure 5, left panel). In other words, individuals with higher $[^{11}\text{C}]PK11195$ binding values in the inferior temporal cortex and medial temporal lobe
regions (as reflected by higher PK(IC3) values) showed: i) increased connectivity between the default mode network, the hippocampus, and other subcortical regions, and ii) weaker connectivity for nodes within the default mode network.

Linking neuroinflammation, connectivity, and cognitive deficits

The first component of the principal component analysis (PCA) of cognitive tests explained the 80% of the variance across the three cognitive measures (with coefficients .61, .61, and .52 for MMSE, ACE-R, and RAVLT, respectively).

Next, we tested whether the effects of neuroinflammation on network connectivity were specific to the patient group and whether this functionally-relevant neuroinflammation related to cognitive deficits. Consistently with this hypothesis, the interaction term between group and brain scores (reflecting how strongly each individual expresses the pattern shown in Fig.5 (which is the brain-wide pattern of functional connections optimised to highly correlate with the IC3- PET derived data) was significantly associated to the first component of the PCA of cognitive tests (t=-3.4, p=0.004).

A post-hoc analysis within each group indicated a significant negative association between the behavioural scores from the PCA and functional connectivity/PK-combined indices in the patient group (r= -0.51, p=0.005) (Figure 5, right panel). Conversely, a non-significant positive direction of association for the same relationship between PCA-derived cognitive scores and brain measures was found in controls (r=0.46, p=0.09). The significant difference between patients and controls remains if AD and MCI+ subgroups are analysed separately (not shown). The negative association in the patient group indicated that patients in whom higher neuroinflammation was more strongly associated with more abnormal connectivity also performed worse on a summary measure of cognitive deficits.
This study establishes a link between the presence of neuroinflammation and the disruption of large-scale functional connectivity in Alzheimer’s disease. The degree to which patients expressed the association between abnormal functional connectivity and neuroinflammation itself correlated with their cognitive deficit. In other words, the patients’ cognitive scores were correlated to a pattern of brain connectivity that was itself linked to microglia activation. This relationship between cognition and a PET-rs-fMRI association (i.e., neuroinflammation relevant functional connectivity) was only seen in patients with Alzheimer’s disease, but not healthy controls. We thus suggest that not only does neuroinflammation relate to large-scale network function, but that the disruption of connectivity linked to neuroinflammation mediates cognitive deficits in Alzheimer’s disease. We argue that the cognitive deficits in Alzheimer’s disease can be directly related to changes in functional connectivity which in turn are mediated by microglia activation, although we acknowledge that there are several mechanisms by which neuroinflammation can alter brain functional connectivity and vice versa (i.e., the ways in which synaptic firing can influence microglia). Microglia are important contributors in the process of synaptic pruning and regulation of synaptic function (Hong et al., 2016). The microglia’s highly mobile and ramified branches can reach and surround synaptic terminals to promote phagocytosis and synaptic demise (Hong et al., 2016). Microglia-induced complement activation might also contribute to synaptic dysfunction and loss, especially in the context of amyloid deposition and neuritic plaque formation (Hong et al., 2016). On the other hand, synaptic firing can influence microglia activation via specific membrane receptors and ion channels (Tofaris and Buckley, 2018).
The anatomical distribution of neuroinflammation in Alzheimer’s disease and its effects on large-scale network function supports the hypothesis that neuroinflammation might be an early event in the pathogenesis of Alzheimer’s disease and that our current results are not driven by a global effect of a systemic inflammatory confound which would have affected the whole-brain indistinctively.

Our study has three implications. First, it supports the use of integrative or multi-modal neuroimaging as a useful tool to improve our understanding of the brain determinants that mediate healthy and pathological ageing (Geerligs and Tsvetanov, 2017).

Second, it reinforces the notion that neuroinflammation is a key pathophysiological mediator of Alzheimer’s disease and its clinical variability (Weiler et al., 2016). Genome-wide association studies have challenged the idea that neuroinflammation is merely a secondary event caused by neurodegeneration and have conversely sustained a primary role of microglia-related molecular pathways in the etio-pathogenesis of Alzheimer’s disease (Guerreiro et al., 2013; Jonsson et al., 2013). For instance, mutations in TREM2, an immune cells receptor expressed on microglia, represent a risk factor for Alzheimer’s and other neurodegenerative diseases (Guerreiro et al., 2013; Jonsson et al., 2013). Together with our results, these data suggest that immuno-therapeutic strategies might be helpful to reduce the deleterious impact of neuroinflammation on cognitive deficits in Alzheimer’s disease.

Third, the functional connectivity abnormalities observed here can be considered an intermediate phenotypic expression of the neuroinflammatory pathology in Alzheimer’s disease. This can be relevant to reconcile the apparent conflict between the encouraging findings from basic research on the role of neuroinflammation in Alzheimer’s pathogenesis (Heppner et al., 2015) and the results from human studies which as yet have provided little
support for immunotherapeutics in Alzheimer’s disease (Adapt Research Group et al., 2007, 2008), despite epidemiological evidence (Breitner and Zandi, 2001; in’t Veld et al., 2001). In other words, assessing how neuroinflammation influences the intermediate phenotypes of large-scale network functional connectivity might help explaining why clinical trials have failed so far to demonstrate a role for immunotherapeutic strategies due to high patient heterogeneity. We showed marked individual differences in the relationship between resting-state functional connectivity and neuroinflammation in patients with Alzheimer’s disease at different stages, and it was this variance that was significantly related to individual differences in cognitive performance.

Our study has also limitations and caveats. First, we recognise that even the multi-variate methods of statistical associations used here do not in themselves demonstrate causality between neuroinflammation, network dysfunction, and cognition. To address this issue, longitudinal and interventional studies are needed, alongside mediation analyses (Fan et al., 2015; Kreisl et al., 2016). Second, we acknowledge that the source-based ‘inflammetry’ of the [$^{11}$C]PK11195 PET data was exploratory in nature, and that we did not perform correction for multiple comparisons in that analysis (although a robust linear regression model was employed to down-weight the effects of extreme data points).

Third, the molecular pathology of Alzheimer’s disease is multi-faceted, with amyloid deposition, tau accumulation, and vasculopathy. These processes, alone or in combination, may moderate the association between neuroinflammation and functional connectivity; hence, multi-modal studies that capture each of these aspects will be useful to formally assess the complex interplay between neuroinflammation, abnormal tau deposition, vasculopathy, and cognitive deficits.
Fourth, the confounding effect of head motion on functional imaging has been fully recognized as both challenging and critical for interpretation of functional imaging studies, especially in clinical populations. To minimize such confound, we used Multi-Echo Independent Components Analysis (ME-ICA) and validated pre-processing pipelines, which separate changes in the fMRI signal that are due to blood oxygenation dependant (BOLD) and non-BOLD signals. Furthermore, we included movement-related parameters as covariates of no interest in second-level analyses, as well as motion and physiological signals in first-level analyses.

Fifth, the use of the $^{[11]}$C]PK11195 tracer has its own limitations in terms of reduced affinity to the mitochondrial translocator protein (TSPO) in activated microglia, especially when compared to second-generation TSPO tracers as PBR28 (Fujita et al., 2017). On the other hand, such second-generation TSPO tracers are affected by common genetic polymorphisms (Owen et al., 2012).

Finally, at the phenotypic level, it remains to be determined whether the deleterious impact of neuroinflammation on network function can be revealed in pre-symptomatic adults at risk of Alzheimer’s disease, for example in carriers of autosomal dominant genetic mutations. Despite the inclusion of patients with mild cognitive impairment with biomarker evidence of Alzheimer’s pathology, our study cannot resolve the timing of neuroinflammation and its causal relationship to network dysfunction, cell loss, and cognitive deficit. There is initial evidence that neuroinflammation may precede abnormal protein aggregation and brain atrophy in pre-symptomatic carriers of MAPT mutations (Bevan-Jones et al., 2019), although further studies are needed to confirm these preliminary findings in patients with Alzheimer’s and other neurodegenerative diseases.
In conclusion, we have shown that source-based ‘inflammetry’ of $[^{11}C]PK11195$ PET data reveals a distributed profile of neuroinflammation in Alzheimer’s disease, which in turn related to abnormal functional connectivity. Our cross-modal multivariate analyses also indicated that heterogeneity in cognitive status was associated to variability in neuroinflammation-related network dysfunction. These data emphasize the value of multi-modal neuroimaging to study how different aspects of the molecular pathology of Alzheimer’s disease mediate brain function and cognition. Improved stratification procedures may facilitate more efficient therapeutic trials in Alzheimer’s disease, based not only on inflammation, tau, atrophy or connectivity, but on their complex interaction that leads to individual differences in cognitive impairment.
**Figure Legends**

**Figure 1.** Schematic representation of various modality datasets in the study, their processing pipelines on a within-subject level (light blue), as well as data-reduction techniques and statistical strategy on between-subject level (dark blue) to test for associations between the datasets. Abbreviations: PKIC (Independent component \[^{11C}\]PK11195 maps); FC (functional connectivity); Cov. (covariates); COG PC1 (latent variable (cognitive deficit) which summarizes the largest portion of shared variance as the first principal component); MMSE (Mini Mental State Examination), ACE-R (Addenbrooke’s Cognitive Examination-Revised); RAVLT (Rey auditory verbal learning test); GM (grey-matter); PiB (Pittsburgh Compound-B positron emission tomography); Cam-CAN (Cambridge Centre for Ageing and Neuroscience); AD/MCI+ (Alzheimer’s disease and MCI PiB positive mild cognitive impairment patients); MLR (multiple linear regression analyses); NIMROD (Neuroimaging of Inflammation in MemoRy and Other Disorders study).

**Figure 2.** Source-Based Inflammmetry for the component differentially expressed between groups: (left) independent component (IC) spatial map reflecting increase in \[^{11C}\]PK11195 (PK) binding values in cortical and subcortical areas including inferior temporal cortex and hippocampus, regionally specific increase over and above global PK differences between groups (regions in red), (right) bar plot of subject loading values for AD/MCI+ and control group (each circle represents an individual) indicating higher loading values for AD/MCI+ than control group as informed by two-sample unpaired permutation test. AD/MCI+ (Alzheimer’s disease and MCI PiB positive mild cognitive impairment patients).

**Figure 3.** The Source-Based Inflammmetry (SBI) identified five independent components (IC) which reflected \[^{11C}\]PK11195 (PK) binding values in cortical and subcortical areas. The PKIC3 component differed between AD/MCI+ patients and controls (first row, third column). This PKIC3 component negatively correlated with total grey-matter volumes in all individuals as well as in patients-only (but not controls-only) (second, third, and fourth rows). In other words, the patients expressing higher \[^{11C}\]PK11195 binding PKIC3 component (reflecting higher binding in the inferior temporal cortex and hippocampus as shown in Figure 2) also displayed higher levels of brain-wide atrophy.
Figure 4. Main effects (left) and group difference effects (AD/MCI+>Controls, right) between default mode network (DMN) and subcortical regions using univariate approach. ACC – anterior cingulate cortex; PCC – posterior cingulate cortex; IPL – intraparietal lobule; FPN – fronto-parietal network; Put – Putamen; Hipp – Hippocampus, AG – angular gyrus; SFG – superior frontal gyrus; R, right; L, left. Note that the whole pattern of brain connectivity rather than each connection separately was employed to study how subject-specific neuroinflammatory levels influence large-scale network connectivity (Fig 5).

Figure 5. (Left) First-level multiple linear regression (MLR) indicating that functional connectivity differences (deviating from groups effects in Figure 3) are associated positively with \[^{11}C\]PK11195-related independent component measures (PKIC3). Connections surviving a threshold of P<0.05 corrected for multiple comparisons are highlighted with a black contour, although it is important to bear in mind that the whole-pattern of brain connectivity was used in the analysis shown in the right panel. (Right) Second-level MLR association between PKIC3 pattern of functional connectivity and cognitive performance for patients with Alzheimer’s disease (AD) pathology (including mild cognitive impairments, amyloid positive, MCI+) (orange) and control (green) groups. The group difference in slopes was significant (p<0.0001). By using multiple linear regression and correlations with cognitive performance, the change in patients’ cognition was found to be correlated to a pattern of brain connectivity that was *itself* linked to inflammation. This relationship between cognition and a PET-rsFMRI association (i.e., neuroinflammation-functional connectivity) was only seen in AD/MCI+ patients, not controls. ACC – anterior cingulate cortex; PCC – posterior cingulate cortex; IPL – intraparietal lobule; FPN – fronto-parietal network; SC – subcortical, DMN – default mode network, DMNd – dorsal DMN, Put – Putamen; Hipp – Hippocampus, AG – angular gyrus; SFG – superior frontal gyrus; R, right; L, left.
References

Adapt Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68:1800–1808.

Adapt Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized controlled trial of naproxen and celecoxib. Arch Neurol 65:896–905.

Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95–113.

Barnett V, Lewis T (1994) Outliers in statistical data. Wiley.

Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer T, Arnold R, Coles JP, Aigbirhio FI, O’Brien JT, Rowe JB (2019) In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. Ann Clin Transl Neurol 6:373–378.

Bevan-Jones WR, Surendranathan A, Passamonti L, Vazquez Rodriguez P, Arnold R, Mak E, Su L, Coles JP, Fryer TD, Hong YT, Williams G, Aigbirhio F, Rowe JB, O’Brien JT (2017) Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open 7:e013187.

Breitner JC, Zandi PP (2001) Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer’s disease? N Engl J Med 345:1567–1568.

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461–467.

Calhoun V, Adali T, Pearlson G, Pekar J (2001) A method for making group inferences from functional MRI data using independent component analysis. Human Brain Mapping 14:140–151.

Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, Walker Z, Turkheimer FE, Brooks DJ (2013) Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology 38:938–949.

Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, Rossor M, Brooks DJ (2008) Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32:412–419.

Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K, Brooks DJ, Edison P (2015) Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement 11:608-21 e7.
Fernandez-Botran R, Ahmed Z, Crespo FA, Gatenbee C, Gonzalez J, Dickson DW, Litvan I (2011) Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism Relat Disord 17:683–688.

Fujita M, Kobayashi M, Ikawa M, Gunn RN, Rabiner EA, Owen DR, Zoghbi SS, Haskali MB, Telu S, Pike VW, Innis RB (2017) Comparison of four (11)C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176-based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Res 7:84.

Geerligs L, Tsvetanov KA (2017) The use of resting state data in an integrative approach to studying neurocognitive ageing–commentary on Campbell and Schacter (2016). Language, Cognition and Neuroscience 32.

Geerligs L, Tsvetanov KA, Cam-Can, Henson RN (2017) Challenges in measuring individual differences in functional connectivity using fMRI: The case of healthy aging. Human Brain Mapping.

Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006a) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412.

Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ (2006b) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 21:89–93.

Grubbs FE (1969) Procedures for Detecting Outlying Observations in Samples. Technometrics 11:1–21.

Guerreiro R et al. (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127.

Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279–287.

Hallquist MN, Hwang K, Luna B (2013) The nuisance of nuisance regression: spectral misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise and obscures functional connectivity. Neuroimage 82:208–225.

Hatashita S, Yamasaki H (2010) Clinically different stages of Alzheimer’s disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 21:995–1003.

Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358–372.

Hoeijmakers L, Heinen Y, van Dam AM, Lucassen PJ, Korosi A (2016) Microglial Priming and Alzheimer’s Disease: A Possible Role for (Early) Immune Challenges and Epigenetics? Front Hum Neurosci 10:398.
Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352:712–716.

Hong S, Stevens B (2016) Microglia: Phagocytosing to Clear, Sculpt, and Eliminate. Dev Cell 38:126–128.

in ’t Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345:1515–1521.

Jenkinson M, Bannister P, Brady M, Smith S (2002) Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:825–841.

Jonsson T et al. (2013) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368:107–116.

Kinahan PE, Rogers JG (1989) Analytic 3D image reconstruction using all detected events. IEEE Transactions on Nuclear Science 36:964–968.

Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, Turner RS, Innis RB (2016) (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiol Aging 44:53–61.

Kundu P, Brenowitz ND, Voon V, Worbe Y, Vértes PE, Inati SJ, Saad ZS, Bandettini PA, Bullmore ET (2013) Integrated strategy for improving functional connectivity mapping using multiecho fMRI. Proceedings of the National Academy of Sciences 110:16187–16192.

Ledoit O, Wolf M (2004) A well-conditioned estimator for large-dimensional covariance matrices. Journal of multivariate analysis 88:365–411.

Li JW, Zong Y, Cao XP, Tan L, Tan L (2018) Microglial priming in Alzheimer’s disease. Ann Transl Med 6:176.

Lindquist M, Geuter S, Wager T, Caffo B (2018) Modular preprocessing pipelines can reintroduce artifacts into fMRI data. bioRxiv:407676.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid
positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 67:754–760.

Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32:1–5.

Passamonti L, Rodríguez PV, Hong YT, Allinson KSJ, Bevan-Jones WR, Williamson D, Jones PS, Arnold R, Borchert RJ, Surendranathan A, Mak E, Su L, Fryer TD, Aigbirhio FI, O’Brien JT, Rowe JB (2018) [11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. Neurology 90:e1989–e1996.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308.

Satterthwaite TD, Elliott MA, Gerraty RT, Ruparel K, Loughead J, Calkins ME, Eickhoff SB, Hakonarson H, Gur RC, Gur RE (2013) An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. Neuroimage 64:240–256.

Schuitemaker A, van Berckel BN, Krogholler MA, Veltman DJ, Scheltens P, Jonker C, Lammertsma AA, Boellaard R (2007) SPM analysis of parametric (R)-[11C]PK11195 binding images: plasma input versus reference tissue parametric methods. Neuroimage 35:1473–1479.

Shafto MA, Tyler LK, Dixon M, Taylor JR, Rowe JB, Cusack R, Calder AJ, Marslen-Wilson WD, Duncan J, Dalgleish T (2014) The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing. BMC neurology 14:204.

Shirer WR, Ryali S, Rykhlevskaia E, Menon V, Greicius MD (2012) Decoding subject-driven cognitive states with whole-brain connectivity patterns. Cerebral cortex 22:158–165.

Stefanetti V, Beccati F, Passamonti F, Sgariglia E, Coletti M, Vuerich M, Marenzoni ML (2016) Detection and DNA quantification of Enterococcus casseliflavus in a foal with septic meningitis. J Am Vet Med Assoc 249:96–100.

Stefaniak J, O’Brien J (2016) Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychiatry 87:21–28.

Thompson B, Borrello GM (1985) The importance of structure coefficients in regression research. Educational and Psychological Measurement 45:203–209.

Tofaris GK, Buckley NJ (2018) Convergent molecular defects underpin diverse neurodegenerative diseases. J Neurol Neurosurg Psychiatry.

Tsvetanov KA, Henson RNA, Tyler LK, Razi A, Geerligs L, Ham TE, Rowe JB (2016) Extrinsic and intrinsic brain network connectivity maintains cognition across the lifespan.
despite accelerated decay of regional brain activation. Journal of Neuroscience 36:3115–3126.

Tsvetanov KA, Ye Z, Hughes L, Samu D, Treder MS, Wolpe N, Tyler LK, Rowe JB, for Cambridge Centre for Ageing and Neuroscience (2018) Activity and connectivity differences underlying inhibitory control across the adult lifespan. The Journal of neuroscience: the official journal of the Society for Neuroscience:2919–17.

Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, Gerhard A, Hinz R, Tai YF, Brooks DJ (2007) Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 48:158–167.

Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr Opin Neurobiol 36:74–81.

Wang MM, Miao D, Cao XP, Tan L, Tan L (2018) Innate immune activation in Alzheimer’s disease. Ann Transl Med 6:177.

Weiler M, Northoff G, Damasceno BP, Balthazar MLF (2016) Self, cortical midline structures and the resting state: Implications for Alzheimer’s disease. Neurosci Biobehav Rev 68:245–255.

Xu L, Groth KM, Pearlson G, Schretlen DJ, Calhoun VD (2009) Source-based morphometry: The use of independent component analysis to identify gray matter differences with application to schizophrenia. Human brain mapping 30:711–724.
Functional connectivity differences associated with $PK_{IC3}$
(First-level MLR)

Neuroinflammatory effects on functional connectivity with disease severity
(Second-level MLR)

Expression of functional connectivity pattern associated with $PK_{IC3}$
- Controls: $r = 0.46, p = 0.096$
- AD/MCI+: $r = -0.51, p = 0.005$
Table 1. Participant details (mean, with standard deviation (SD) and range in parentheses) and group differences by chi-squared test, one-way analysis of variance or independent samples t-test. AD/MCI+: Alzheimer’s disease/mild cognitive impairment (amyloid positive on Pittsburgh Compound-B positron emission tomography scan); MMSE: Mini Mental State Examination; ACE-R: Addenbrooke’s Cognitive Examination Revised, RAVLT: Rey Auditory-Verbal Learning Test (delayed recall). NS, not significant with p>0.05 (uncorrected).

| Demographic & Clinical data | AD/MCI+ (N=28) | Controls (N=14) | AD/MCI+<Controls |
|-----------------------------|----------------|-----------------|------------------|
| Sex (females/males)         | 12/16          | 8/6             | NS               |
| Age (years) (SD, range)     | 72.7 (±8.5, 53-86) | 68.3 (±5.4, 59-81) | NS               |
| Education (years) (SD, range) | 12.9 (±3.0, 10-19) | 14.1 (±2.7, 10-19) | NS               |
| MMSE (SD, range)            | 25.6 (±2.2, 21-30) | 28.8 (±1.0, 27-30) | T=4.9, P<0.0001  |
| ACE-R (SD, range)           | 78.9 (±7.7, 62-91) | 91.6 (±5.3, 79-99) | T=5.5, P<0.0001  |
| RAVLT (SD, range)           | 1.5 (±1.6, 0-6)  | 9.6 (±3.2, 3-15)  | T=10.8, P<0.0001 |